During the last financial year, the Group made progress in its four strategic objectives in terms of sustainability and social responsibility: patient care; The environmental protection; the development of the local communities where it operates and the well-being of its staff. These objectives are present in the statutes of all Chiesi subsidiaries around the world. Chiesi is committed to sustainable value generation for patients by providing innovative therapeutic solutions. In 2022, the Group invested 589 million euros in research and development (R&D), a figure that represents an increase of 7% compared to the previous year and represents 21.4% of total revenue. Chiesi continues to advance its commitment to clinical trial transparency and data communication beyond mandatory requirements. The Group discloses clinical protocols, study-related information and summary results in public registries on a global scale. During this period, Chiesi has increased its participation in activities with different patient groups, as well as the expansion of projects and initiatives that enhance patient participation in the health system.